Bionano Genomics

Precision Medicine And Genomic Tools Will Expand Clinical Adoption

AnalystHighTarget

Not Invested

Consensus Narrative from 2 Analysts

Published

24 Aug 25

Updated

28 Aug 25

AnalystHighTarget's Fair Value

US$11.00

64.5% undervalued

28 Aug

US$3.90

-86.4%

14.4%

-86.4%

14.4%

Author's Valuation

US$11.0

64.5% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$11.0

64.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

24.21%

Life Sciences revenue growth rate

0.32%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

9.23%

Calculation

US$15.66m

Earnings '28

9.40x

PE Ratio '28

US$147.20m

Market Cap '28

US$147.20m

Market Cap '28

10.28m

No. shares '28

US$14.31

Share Price '28

US$14.31 Share Price '28

Discounted to 2025 @ 9.17% p.a.

US$11.00

Fair Value '25